TrialNature communications2026

Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Anna Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.